CORE LABORATORIES INC.

CLB

CIK 0001958086 · Quarterly mode · latest period FY2025 (Q4) (ending 2025-12-31) · sourced from SEC EDGAR

At a glance · FY2025 (Q4)

Revenue
$138M
↑+7.0% +$9Mvs FY2024 (Q4)
Operating Income
$16M
↑+11.7% +$2Mvs FY2024 (Q4)
Net Income
$5M
↓-33.2% -$2Mvs FY2024 (Q4)
Gross Profit
$29M
↑+24.7% +$6Mvs FY2024 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Average
53/100
  • Profitability
    25ROIC 9.9% (10% = solid, 20%+ = moat)
  • Liquidity
    76Current Ratio 2.02 (above 1.5 = solid)
  • Leverage
    79D/E 0.42 (under 0.5 = conservative)
  • Efficiency
    54Asset Turnover 0.90x (1.0+ = capital-efficient)
  • Growth
    40Revenue YoY +7.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    41Op Margin 11.5% · trend -0.6pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

DCF intrinsic value

DCF intrinsic value

two-stage Gordon model

Project CLB's free cash flow forward, discount back at your hurdle rate, divide by diluted shares. Edit the assumptions to see how sensitive the intrinsic value is.

21%

Trailing 3-yr CAGR was 20.5%

10%

10% is a common all-equity benchmark for US large-caps

2.5%

Should be ≤ long-run GDP growth (~2.5% nominal)

5

5-year explicit projection + perpetuity terminal

Intrinsic value per share
$15.77
Total enterprise IV
$742M
Diluted shares
0.05B
Terminal PV
$568M (77% of total)
Year-5 FCF
$67M
YearProjected FCFDiscounted PV
+1$31M$28M
+2$38M$31M
+3$46M$34M
+4$55M$38M
+5$67M$42M
Terminal$915M$568M

DCF outputs are HIGHLY sensitive to growth + WACC assumptions. A 1pp WACC change can shift IV by 20%+. Use this as a sanity-check vs market price, not a target — and always cross-check the underlying FCF source (EDGAR cashflow statement, latest annual). Margin of safety convention: 30-50% discount to IV before buying.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$11M
investment in PP&E
Dividends paid (TTM)
$2M
cash returned to holders
Stock buybacks (TTM)
$12M
share count reduction
Stock-based comp (TTM)
$7M
non-cash dilution

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$584M
everything owned
Stockholders' equity
$266M
shareholder claim
Net debt
$90M
LT debt minus cash

Recent performance · 15 quarters

Revenue↑+7.0% +$9M
$138M
Net Income↓-33.2% -$2M
$5M
Free Cash Flow↓-71.2% -$12M
$5M
Operating Margin↑+0.5pts
11.5%

Drill down